NASDAQ$OLMA
Olema Pharmaceuticals Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Olema Oncology reported financial results for the second quarter of 2021 and provided a corporate update.
Olema Oncology reported a net loss of $16.4 million for the second quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $318.1 million as of June 30, 2021, expected to fund operations through the end of 2023.
- Advanced the Phase 1/2 clinical trial of OP-1250 in patients with metastatic, ER+ / HER2- breast cancer, enrolling 28 patients across five dose-escalation cohorts as of June 4, 2021.
- OP-1250 demonstrated oral bioavailability and a dose-proportional pharmacokinetic profile.
- Interim safety, tolerability, pharmacokinetic, and initial efficacy data presentation planned for Q4 2021.
- Cash, cash equivalents and marketable securities as of June 30, 2021 were $318.1 million, anticipated to fund operations through the end of 2023.
Headline financials
Revenue & EPS history
Olema · Revenue · Quarterly
$0
Forward guidance
Olema Oncology anticipates presenting preliminary Phase 1/2 dose-escalation data for OP-1250 in patients with metastatic, ER+ / HER2- breast cancer in Q4 2021. The company expects its cash balance to be sufficient to fund operations through the end of 2023.
Tailwinds
- Presentation of preliminary Phase 1/2 dose-escalation data for OP-1250 in patients with metastatic, ER+ / HER2- breast cancer planned for Q4 2021.
- Advancement into monotherapy dose expansion in the second half of 2021.
- Initiation of a Phase 1b clinical trial of OP-1250 in combination with a CDK4/6 inhibitor in the first quarter of 2022.
- OP-1250 has demonstrated oral bioavailability.
- A maximum tolerated dose has not been identified.
Headwinds
- The risk that Olema’s ongoing or future clinical studies in humans may show that OP-1250 is not a tolerable and effective treatment for breast cancer
- Olema's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 to be filed on August 10, 2021
- Various risks and uncertainties, and actual results, performance or achievements of Olema could differ materially from those described in or implied by the statements in this press release.
- Olema is a clinical-stage biopharmaceutical company
- Net loss for the quarter ended June 30, 2021 was $16.4 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
-0.1%
Avg return
Earnings day
-2.4%
Avg return
5 days after
+7.5%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+17.0%
Q4 2021
Best reaction
-28.5%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.2% | -7.7% | -29.4% | |
| Q3 2025 | +4.1% | +0.6% | +267.4% | |
| Q2 2025 | +16.0% | +20.6% | +75.1% | |
| Q1 2025 | +2.1% | +9.6% | -11.0% | |
| Q4 2024 | -8.5% | +4.3% | +6.8% | |
| Q3 2024 | -9.7% | -27.9% | -47.2% | |
| Q1 2024 | -12.5% | -18.0% | +16.8% | |
| Q4 2023 | -6.6% | -11.2% | -15.8% | |
| Q3 2023 | -7.6% | -7.4% | -29.2% | |
| Q2 2023 | +15.3% | +14.0% | +24.7% | |
| Q1 2023 | +1.1% | +6.1% | -0.3% | |
| Q4 2022 | +0.0% | +0.3% | -15.4% | |
| Q3 2022 | -7.2% | +5.6% | -22.5% | |
| Q2 2022 | -28.5% | -29.4% | -23.1% | |
| Q1 2022 | -1.3% | -3.1% | +79.4% | |
| Q4 2019 | +17.0% | -2.2% | -5.9% | |
| Q4 2021 | +17.0% | -2.2% | -5.9% | |
| Q3 2021 | +1.1% | -1.9% | -61.9% | |
| Q3 2020 | +1.1% | -1.9% | -61.9% | |
| Q2 2020 | +3.4% | +1.9% | +11.2% | |
| Q2 2021 | +3.4% | +1.9% | +11.2% | |
| Q1 2021 | +11.9% | +14.8% | +35.8% | |
| Q4 2020 | -10.2% | -23.2% | -27.2% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro